China Biologic Products Inc (CBPO) reported quarterly earnings results on Wednesday, May-4-2016. The company said it had a profit of $1.09 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.21. Analysts had a consensus of $0.88. The company posted revenue of $85.60 million in the period. The company’s revenue was up 21.6% compared to the same quarter last year.
Many Wall Street Analysts have commented on China Biologic Products Inc. China Biologic Products Inc was Downgraded by Credit Suisse to ” Neutral” on Mar 1, 2016.
China Biologic Products Inc opened for trading at $117.44 and hit $120.945 on the upside on Monday, eventually ending the session at $120.43, with a gain of 2.93% or 3.43 points. The heightened volatility saw the trading volume jump to 2,96,878 shares. Company has a market cap of $3,202 M.
In a different news, on Mar 15, 2016, Zhijing Cbpo Liu (Corporate Vice President) sold 282 shares at $108.00 per share price. According to the SEC, on Mar 9, 2016, Min Fang (director) sold 4,257,000 shares at $107.00 per share price. On Dec 8, 2015, Zhijun Tong (director) sold 15,000 shares at $118.67 per share price, according to the Form-4 filing with the securities and exchange commission.
China Biologic Products Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research development manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries namely Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co. Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co. Ltd. a plasma products company. Its products include human albumin human immunoglobulin IVIG thymopolypeptides injection human hepatitis B immunoglobulin human rabies immunoglobulin human tetanus immunoglobulin placenta polypeptide Factor VIII and human prothrombin complex concentrate (PCC).